US Patent

US9649280 — Composition comprising hydrocortisone

Method of Use · Assigned to Diurnal Ltd · Expires 2034-05-12 · 8y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a pharmaceutical composition useful in treating adrenal insufficiency in pediatric or elderly subjects.

USPTO Abstract

The disclosure relates to pharmaceutical compositions useful in the treatment of adrenal insufficiency in paediatric or elderly subjects.

Drugs covered by this patent

Cortef (hydrocortisone) · Generic (originally Merck/Upjohn)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3075`	—	Cortef
`U-3075`	—	Cortef
`U-3075`	—	Cortef
`U-3075`	—	Cortef

Patent Metadata

Patent number: US9649280
Jurisdiction: US
Classification: Method of Use
Expires: 2034-05-12
Drug substance claim: No
Drug product claim: Yes
Assignee: Diurnal Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.